2016-2014 | 2013-2011 | 2010-2006 | 2005-2000 | 1999-1991

2016-2014

Atkinson C, Ray RM, Li W, Lin MG, Gao DL, Shannon J, Stalsberg H, Porter PL, Frankenfeld CL, Wähälä K, Thomas DB, Lampe JW. Plasma equol concentration is not associated with breast cancer and fibrocystic breast conditions among women in Shanghai, China. Nutr Res. 36(8):863-871, 2016. PMID: 27440541

Chen L, Cook LS, Tang MT, Porter PL, Hill DA, Wiggins CL, Li CI. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer. Breast Cancer Res Treat. 157(3):545-54, 2016. PMID: 27220749

Bluestein BM, Morrish F, Graham DJ, Guenthoer J, Hockenbery D, Porter PL, Gamble LJ. An unsupervised MVA method to compare specific regions in human breast tumor tissue samples using ToF-SIMS. Analyst 141(6):1947-57, 2016. PMID: 26878076

Scheel JR, Nealey EM, Orem J, Bugeza S, Muyinda Z, Nathan RO, Porter PL, Lehman CD. ACR BI-RADS Use in Low-Income Countries: An Analysis of Diagnostic Breast Ultrasound Practice in Uganda. J Am Coll Radiol. 13(2):163-169, 2016. PMID: 26419306

Polley MY, Leung SC, Gao D, Mastropasqua MG, Zabaglo LA, Bartlett JM, McShane LM, Enos RA, Badve SS, Bane AL, Borgquist S, Fineberg S, Lin MG, Gown AM, Grabau D, Gutierrez C, Hugh JC, Moriya T, Ohi Y, Osborne CK, Penault-Llorca FM, Piper T, Porter PL, Sakatani T, Salgado R, Starczynski J, Lænkholm AV, Viale G, Dowsett M, Hayes DF, Nielsen TO. An international study to increase concordance in Ki67 scoring. Mod Pathol. 28(6):778-786, 2015. PMID: 25698062

Zhao H, Faltermeier CM, Mendelsohn L, Porter PL, Clurman BE, Roberts JM. Mislocalization of p27 to the cytoplasm of breast cancer cells confers resistance to anti-HER2 targeted therapy. Oncotarget. 5(24):12704-12714, 2014. PMID: 25587029

Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA, Linden HM. A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC). Mol Imaging Biol 16(3):431-40, 2014. PMID: 24170452

Cai X, Dai Z, Reeves RS, Caballero-Benitez A, Duran KL, Delrow JJ, Porter PL, Spies T, Groh V. Autonomous stimulation of cancer cell plasticity by human NKG2D lymphocyte receptor coexpressed with its ligands on cancer cells. PLoS One 9(10):e108942, 2014. PMID: 25291178

Li CI, Daling JR, Haugen KL, Tang MT, Porter PL, Malone KE. Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age. Breast Cancer Res Treat 145(2):481-9, 2014. PMID: 24748570

Beaber EF, Malone KE, Tang MT, Barlow WE, Porter PL, Daling JR, Li CI. Oral contraceptives and breast cancer risk overall and by molecular subtype among young women. Cancer Epidemiol Biomarkers Prev 23(5):755-64, 2014. PMID: 24633144

2013-2011

McDougall JA, Malone KE, Daling JR, Cushing-Haugen KL, Porter PL, Li CI. Long-term statin use and risk of ductal and lobular breast cancer among women 55-74 years of age. Cancer Epidemiol Biomarkers Prev. 2013 Jul 5. [Epub ahead of print] PubMed PMID: 23833125.

Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, Szymonifka J, Bhan AK, Shepherd LE, Zhang Y, Schnabel CA, Erlander MG, Ingle JN, Porter P, Muss HB, Pritchard KI, Tu D, Rimm DL, Goss PE. Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker. J Natl Cancer Inst. 2013 17;105(14):1036-1042. Epub 2013 Jun 28. PMID: 23812955.

Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE. Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age. Breast Cancer Res Treat. 2013 137(2):579-87. Epub 2012 Dec 9. PMID: 23224237; PMCID: PMC3547981.

Li CI, Daling JR, Tang MT, Haugen KL, Porter PL, Malone KE. Use of Antihypertensive Medications and Breast Cancer Risk Among Women Aged 55 to 74 Years. JAMA Intern Med. 2013 [Epub ahead of print] PubMed PMID: 23921840.

Kamineni A, Anderson ML, White E, Taplin SH, Porter P, Ballard-Barbash R, Malone K, Buist DS. Body mass index, tumor characteristics and prognosis following the diagnosis of early-stage breast cancer in a mammographically screened population. Cancer Causes Control. 2013 24(2):305-12. Epub 2012 Dec 7.PMID: 23224272; PMCID: PMC3557530

Li CI, Beaber EF, Tang MT, Porter, PL, Daling JR, Malone KE. Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. Cancer Res. 2012. 72:2028-35. PMCID:PMC3328650.

Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I, True L, Nelson PS. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 2012 Sep;18(9):1359-68. PubMed PMID: 22863786; PubMed Central PMCID: PMC3677971.

Amon LM, Pitteri SJ, Li CI, McIntosh M, Ladd JJ, Disis M, Porter P, Wong CH, Zhang Q, Lampe P, Prentice RL, Hanash SM. Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer. Cancer Res. 2012 Apr 15;72(8):1935-42. doi: 10.1158/0008-5472.CAN-11-3266. Epub 2012 Feb 24. PMID: 22367215

Kamineni A, Anderson ML, White E, Taplin SH, Porter P, Ballard-Barbash R, Malone K, Buist DS. Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population. Cancer Causes Control. 2012 Dec 7. [Epub ahead of print] PMID: 23224272

Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE. Reproductive factors and risk of estrogen receptor positive, triple-negative and HER2-neu overexpressing breast cancer among women 20-44 years of age. Breast Cancer Res Treat. 2012 Dec 9. [Epub ahead of print] PMID: 23224237

Amon LM, Pitteri SJ, Li CI, McIntosh M, Ladd JJ, Disis M, Porter P, Wong CH, Zhang Q, Lampe P, Prentice RL, Hanash SM. Concordant Release of Glycolysis Proteins into the Plasma Preceding a Diagnosis of ER+ Breast Cancer. Cancer Res. 2012. 72(8):1935-42. PMID: 22367215.

Li CI, Beaber EF, Chen Tang MT, Porter PL, Daling JR, Malone KE. Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20-44 years of age. Cancer Res. 2012 Apr 15;72(8):2028-35. PMCID:PMC3328650.

Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, O'meara ES, Li CI. Breast Density, Body Mass Index, and Risk of Tumor Marker-Defined Subtypes of Breast Cancer. Ann Epidemiol. 2012 Feb 25. [Epub ahead of print] PubMed PMID: 22366170.

Guenthoer J, Diede SJ, Tanaka H, Chai X, Hsu L, Tapscott SJ, Porter PL. Assessment of palindromes as platforms for DNA amplification in breast cancer. Genome Res. 2012 Feb;22(2):232-45. PMCID: PMC3266031.

Malone KE, Daling JR, Doody DR, O'Brien C, Resler A, Ostrander EA, Porter PL. Family history of breast cancer in relation to tumor characteristics and mortality in a population-based study of young women with invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec;20(12):2560-71. PMCID: PMC3242640.

Harford JB, Otero IV, Anderson BO, Cazap E, Gradishar WJ, Gralow JR, Kane GM, Niëns LM, Porter PL, Reeler AV, Rieger PT, Shockney LD, Shulman LN, Soldak T, Thomas DB, Thompson B, Winchester DP, Zelle SG, Badwe RA. Problem solving for breast health care delivery in low and middle resource countries (LMCs): consensus statement from the Breast Health Global Initiative. Breast. 2011 Apr;20 Suppl 2:S20-9. Epub 2011 Mar 4. PMID: 21376593

Loo LW, Wang YW, Flynn EM, Lund MJ, Aiello-Bowles EJ, Buist DSM, Liff JM, Flagg EW, Coates RJ, Eley JW, Hsu L, Porter PL. Genome-wide Copy Number Alterations in Subtypes of Invasive Breast Cancers in Young White and African American Women. Breast Cancer Res Treat; 127(1):297-308, 2011. Epub 2011 Jan 25. NIHMSID: NIHMS318789

Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, Li, CI. Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control; 22(3):399-405, 2011. Epub 2010 Dec 24. PMCID: PMC3042513

Reding KW, Doody DR, McTiernan A, Hsu L, Davis S, Daling JR, Porter PL, Malone KE. Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer. Breast Cancer Res Treat;126(3):749-61, 2011. Epub 2010 Sep 29. PMCID: PMC3059400

Ton CC, Vartanian N, Chai X, Lin MG, Yuan X, Malone KE, Li CI, Dawson A, Sather C, Delrow J, Hsu L, Porter PL. Gene expression array testing of FFPE archival breast tumor samples: an optimized protocol for WG-DASL sample preparation. Breast Cancer Res Treat;125(3):879-83, 2011. Epub 2010 Sep 15. PMCID: PMC3124315

Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, Li CI. Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk. Breast Cancer Res Treat; 126(3):671-8, 2011. Epub 2010 Sep 3. PMCID: PMC3059326

Harigopal M, Barlow WE, Tedeschi G, Porter PL, Yeh IT, Haskell C, Livingston R, Hortobagyi GN, Sledge G, Shapiro C, Ingle JN, Rimm DL, Hayes DF. Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. Am J Pathol; 176(4):1639-47, 2010. Epub 2010 Feb 11. PMCID: PMC2843456

2010-2006

Nelson ZC, Ray RM, Wu C, Stalsberg H, Porter P, Lampe JW, Shannon J, Horner N, Li W, Wang W, Hu Y, Gao D, Thomas DB. Fruit and vegetable intakes are associated with lower risk of breast fibroadenomas in Chinese women. J Nutr;140(7):1294-301, 2010. Epub 2010 May 19. PMCID: PMC2884330

Porter, PL. Global Trends in Breast Cancer Incidence and Mortality. Salud Publica de Mexico, 51:S141-146, 2009. PMID: 19967268

Li CI, Daling JR, Porter PL, Tang MT, Malone KE. Relationship Between Potentially Modifiable Lifestyle Factors and Risk of Second Primary Contralateral Breast Cancer Among Women Diagnosed With Estrogen Receptor-Positive Invasive Breast Cancer. J Clin Oncol; 27(32):5312-8, 2009. Epub 2009 Sep 8. PMCID: PMC2773216

Li CI, Daling JR, Porter PL, Tang MT, Malone KE. Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer. Cancer Res, 69:6865-6870, 2009. PMCID: PMC2745902

Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, Malone KE. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev, 18:1157-1166, 2009. PMCID: PMC2754710

Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW. Race and triple negative threats to breast cancer survival: A population-based study in Atlanta. Breast Cancer Res Treat, 113:357-370, 2009. PMID: 18324472

Trivers KF, Lund MJ, Porter PL, Liff JM, Flagg EW, Coates RJ, Eley JW. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control, 20:1071–1082, 2009. PMID: 19343511

Phipps Al, Malone KE, Porter PL, Daling JR, Li Cl. Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev, 17(8):2078-2086. 2008. PMCID:PMC2561180.

Reding KW, Daling JR, Doody DR, O’Brien CA, Porter PL, Malone KE. Effect of prediagnostic alcohol consumption on survival after breast cancer in young women. Cancer Epidemiol Biomarkers Prev, 17(8):1988-1996. 2008. PMCID:PMC2605937.

Phipps A, Malone K, Porter P, Daling J, Li CI. Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer, 113:1521-1526, 2008. PMCID:PMC2587413

McTiernan A, Porter P, Potter JD. Breast cancer prevention in countries with diverse resources. Cancer 113(8 Suppl):2325-30, 2008.

Gadi VK, Malone KE, Guthrie KA, Porter PL, Nelson JL. Case-control study of fetal microchimerism and breast cancer. PLoS One 5;3(3):e1706. 2008. PMID: 18320027

Mathes R, Malone K, Daling J, Davis S, Lucas S, Porter P, Li CI. Migraine in postmenopausal women and the risk of invasive breast cancer. Cancer Epidemiol Biomarkers Prev, 17:3116-122, 2008. PMCID:PMC2692343.

Beaber E, Holt V, Malone K, Porter PL, Daling J, Li C. Reproductive factors, age at maximum height, and risk of three histologic types of breast cancer. Cancer Epidemiol Biomarkers Prev, 17:3427-3434, 2008. PMCID:PMC2652475

Loo LW, Ton C, Wang YW, Grove DI, Bouzek H, Vartanian N, Lin MG, Yuan X, Lawton TL, Daling JR, Malone KE, Li CI, Hsu L, Porter PL. Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer. Genes Chromosomes Cancer, 47:1049-1066, 2008. PMCID:PMC2871767

Mathes RW, Malone KE, Daling JR, Porter PL, Li CI. Relationship between histamine2-receptor antagonist medications and risk of invasive breast cancer. Cancer Epidemiol Biomarkers Prev, 17:67-72, 2008

Porter PL. “Westernizing” Women’s Risks? Breast Cancer in Lower-Income Countries. NEJM, 358: 213-216, 2008.

Trivers KF, Gammon MD, Abrahamson PE, Lund MJ, Flagg EW, Moorman PG, Kaufman JS, Cai J, Porter PL, Brinton LA, Eley JW, Coates RJ. Oral contraceptives and survival in breast cancer patients aged 20 to 54 years. Cancer Epidemiol Biomarkers Prev, 16:1822-1827, 2007.

Chin SF, Teschendorff AE, Marioni JC, Wang Y, Barbosa-Morais NL, Thorne NP, Costa JL, Pinder SE, van de Wiel MA, Green AR, Ellis IO, Porter PL, Tavare S, Brenton JD, Ylstra B, Caldas C. High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol, 8:R215, 2007.

Lampe J, Nishino Y, Ray R, Wu C, Li W, Lin M-G, DL Gao, Hu Y, Shannon J, Stalsberg H, Porter PL, Frankenfeld C, Wähälä K, Thomas DB. Plasma Isoflavones and Fibrocystic Breast Conditions and Breast Cancer Among Women in Shanghai, China. Cancer Epidemiol Bio Prev, 16: 2579-2586, 2007.

Hahn KM, Bondy ML, Selvan M, Lund MJ, Liff JM, Flagg EW, Brinton LA, Porter P, Eley JW, Coates RJ. Factors Associated with Advanced Disease Stage at Diagnosis in a Population-based Study of Patients with Newly Diagnosed Breast Cancer. Am J Epidemiol, 166:1035-1044, 2007.

Katz A, Saad ED, Porter P, and Pusztai L. Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol, 8: 55-62, 2007.

Porter PL, Barlow WE, Yeh I-T, Lin M-G, Yuan X, Donato E, Sledge GW, Shapiro CL, Ingle JN, Haskell CM, Albain KS, Roberts JM, Livingston RB, Hayes DF. p27Kip1 and Cyclin E Expression and Breast Cancer Survival After Treatment With Adjuvant Chemotherapy. J. Natl. Cancer Inst. 98(23):1723-1731, 2006.

Timmerbeul I, Garrett-Engele CM, Kossatz U, Chen X, Firpo E, Grunwald V, Kamino K, Wilkens L, Lehman U, Buer J, Geffers R, Kubicka S, Manns MP, Porter PL, Roberts JM, Malek NP. Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer. Proc Natl Acad Sci U S A. 19;103(38):14009-14, 2006.

Trivers KF, Gammon MD, Abrahamson PE, Lund MJ, Flagg EW, Kaufman JS, Moorman PG, Cai J, Olshan AF, Porter PL, Brinton LA, Eley JW, and Coates RJ. Association between reproductive factors and breast cancer survival in younger women. Breast Cancer Res Treat, 103: 93-102, 2007.

Abrahamson PE, Gammon MD, Lund MJ, Flagg EW, Porter PL, Stevens J, Swanson CA, Brinton LA, Eley JW, Coates RJ. General and abdominal obesity and survival among young women with breast cancer. Ca Epidemiol Biomarkers Prev 15(10):1871-1877, 2006

Abrahamson PE, Gammon MD, Lund MJ, Britton JA, Marshall SW, Flagg EW, Porter PL, Brinton LA, Eley JW, Coates RJ. Recreational physical activity and survival among young women with breast cancer. Cancer 107(8):1777-1785, 2006.

Rao K, Alper O, Opheim K, Bonnet G, Wolfe K, Bryant E, Larrivee S, Porter P, McDougall J. Cytogenetic characterization and H-ras associated transformation of immortalized human mammary epithelial cells. Cancer Cell Int. 6(1):15, 2006.

2005-2000

Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, Carter JJ, Porter PL, Galloway DA, McDougall JK, Krieger JN. Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer. 116(4):606-16, 2005.

Hsu L, Self SG, Grove D, Randolph T, Wang K, Delrow JJ, Loo L, Porter P. Denoising array-based comparative genomic hybridization data using wavelets. Biostatistics 6(2):211-26, 2005.

•Aiello EJ, Buist DSM, White E, Porter PL. Association between mammographic breast density and breast cancer tumor characteristics. Ca Epidemiol Biomarkers Prev. 14(3):662-8, 2005.

Shannon J, Ray RM, Wu C, Nelson ZC, Gao DI, Li W, Wei HY, Lampe JW, Horner N, Satia JA, Patterson RE, Fitzgibbons ED, Porter PL, Thomas DB. Food and botanical grouping and risk of breast cancer: a case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 14(1):81-90, 2005.

Loo L, Grove D, Neal C, Williams E, Cousens L, Schubert E, Holcomb I, Massa H, Glogovac J, Li CI, Malone K, Daling J, Delrow J, Trask B, Hsu L, Porter PL. Array CGH Analysis of Genomic Alterations in Breast Cancer Sub-Types. Cancer Research 64(23):8541-9, 2004.

Wu C, Ray RM, Lin MG, Gao DL, Horner NK, Nelson ZC, Lampe JW, Hu YW, Shannon J, Stalsberg H, Li W, Fitzgibbons D, Porter P, Patterson RE, Satia JA, Thomas DB. A case-control study of risk factors for fibrocystic breast conditions: Shanghai Nutrition and Breast Disease Study, China, 1995-2000. Am J Epidemiol 160(10):945-60, 2004.

Buist DSM, Porter PL, Lehman C, Taplin SG, White JE. Factors contributing to mammography failure in women aged 40-49 years. JNCI 96(19):1432-40, 2004.

Sparks R, Ulrich CM, Bigler J, Tworoger SS, Yasui Y, Rajan KB, Porter P, Stanczyk FZ, Ballard-Barbash R, Yuan X, Lin MG, McVarish L, Aiello EJ, McTiernan A. UDP-glucuronosyltransferase and sulfotransferase polymorphisms, sex hormone concentrations, and tumor receptor status in breast cancer patients. Breast Cancer Res 6(5):R488-98, 2004.

Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, Carter JJ, Porter PL, Galloway DA, McDougall JK. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 101(2):270-80, 2004.

Porter PL, Lund MJ, Lin MG,Yuan X, Liff JM, Flagg EW, Coates RJ, Eley JW. Racial differences in expression of cell cycle regulatory proteins in breast carcinoma: Study of young African American and white women in Atlanta, Georgia. Cancer 100:2533-2542, 2004.

Oestreicher N, White JE, Malone KE, Porter PL. Hormonal factors and breast tumor proliferation: Do factors that affect cancer risk also affect tumor growth? Breast Cancer Res Treat 85:133-142, 2004.

Suter NM, Ray RM, Hu YW, Lin MG, Porter PL, Gao DL, Zaucha RE, Iwasaki LM, Sabacan LP, Langlois MC, Thomas DB, Ostrander EA. BRCA1 and BRCA2 mutations in women from Shanghai China. Cancer Epidemiol Biomarkers Prev 13(2):181-189, 2004.

Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Daling JR. The relationship between alcohol use and risk of breast cancer by histology and hormone receptor status among women 65-79 years of age. Cancer Epidemiol Biomarkers Prev 12(10):1061-1066, 2003.

Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Daling JR. Reproductive and anthropometric factors in relation to the risk of lobular and ductal breast carcinoma among women 65-79 years of age. Int J Cancer 107(4):647-651, 2003.

Li CI, Malone KE, Porter PL, Daling JR. Epidemiologic and molecular risk factors for contralateral breast cancer among young women. Br J Cancer 89(3):513-518, 2003.

Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL, Daling JR. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289(24):3254-3263, 2003.

Madeleine MM, Brumback B, Cushing-Haugen KL, Schwartz SM, Daling JR, Smith AG, Nelson JL, Porter PL, Shera KA, McDougall JK, Galloway DA. Human leukocyte antigen class II and cervical cancer risk: a population-based study. J Infect Dis 186(11):1565-74, 2002.

Thomas DB, Gao DL, Ray RM, Wang WW, Allison CJ, Chen FL, Porter PL, Hu YW, Zhao GL, Pan LD, Li W, Wu C, Coriaty Z, Evans I, Lin MG, Stalsberg H, Self SG. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 94:1445-1457, 2002.

Oestreicher N, White JE, Lehman CD, Mandelson MT, Porter PL, Taplin SH. Predictors of sensitivity of clinical breast examination. Breast Cancer Res Treat 76:73-81, 2002.

Daling JR, Malone KE, Doody DR, Anderson BO, Porter PL. The relation of reproductive factors to mortality from breast cancer. Cancer Epidemiol, Biomarkers & Prev 11:235-241, 2002.

Daling JR, Madeleine MM, Schwartz SM, Shera K, McKnight B, Carter JC, Porter PL, Galloway DA, McDougall JK, Tamimi H. A population-based study of squamous cell vaginal cancer: HPV and co-factors. Gynecol Oncol 84:263-270, 2002.

Barrett MT, Glogovac J, Prevo LJ, Reid BJ, Porter PL, Rabinovitch PS. High quality RNA and DNA from flow cytometrically sorted human epithelial cells and tissues. Biotechniques 32:888-896, 2002.

Schubert EL, Hsu L, Cousens LA, Glogovac J, Self S, Reid BJ, Rabinovitch P, Porter PL. Single nucleotide polymorphism array analysis of flow-sorted epithelial cells from frozen versus fixed tissues for whole genome analysis of allelic loss in breast cancer. Am J Path 160(1):73-79, 2002.

Chen C, Ricks S, Doody DR, Fitzgibbons ED, Porter PL and Schwartz SM. N-Acetlytransferase 2 polymorphisms, cigarette smoking and alcohol consumption, and oral squamous cell cancer risk. Carcinogenesis 22:1993-1999, 2001.

Porter PL. Molecular Markers of Tumorigenesis. Review, Current Opinion Genetics and Development 11:60-63, 2001.

Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL. Relationship of body mass index to tumor markers and survival among young women with breast cancer. Cancer 92:720-729, 2001.

Carter JJ, Madeleine MM, Shera K, Schwartz SM, Cushing-Haugen K, Wipf GC, Porter PL, Daling JR, McDougall JK, Galloway DA. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res 61:1934-1940, 2001.

Schwartz SM, Daling JR, Shera KA, Madeleine MM, McKnight B, Galloway DA, Porter PL, McDougall JK. Human papillomavirus and prognosis of invasive cervical cancer: A population-based study. J Clin Oncol 19:1906-1915, 2001.

Madeleine MM, Schwartz SM, Daling JR, Shera K, McKnight B, Carter JJ, Wipf GC, Critchlow CW, McDougall JK, Porter PL, Galloway DA. Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers & Prev 10:171-177, 2001.

Mandelson MT, Oestriecher N, Porter PL, Taplin SH, White JE. Mammographic Breast Density in Relation to Interval vs. Screen-detected Cancer. J Natl Cancer Inst 92:1081-1087, 2000.

1999-1991

Li CI, Anderson BO, Porter PL, Holt SK, Daling JR, Moe RE. Changing incidence rate of invasive lobular carcinoma among older women. Cancer 88:2561-2569, 2000.

Porter PL, El-Bastawissi AY, Mandelson M, Lin MG, Khalid N, Watney EA, Cousens L, White D, Taplin S, White E. Breast Tumor Characteristics as Predictors of Detection by Mammography: Comparison of Interval and Screen-detected Cancers in a Defined Population. J Natl Cancer Inst 91(23):2020-2028, 1999.
Clurman BE, Porter PL. New insights into the tumor suppression functions of p27Kip1. Proc Natl Acad Sci USA, 95:15158-15160, 1998.

Habel LA, Daling JR, Newcomb PA, Self SA, Porter PL, Stanford JL, Seidel K, Weiss NS. Risk of Recurrence after Ductal Carcinoma in Situ of the Breast. Cancer Epidemiol, Biomarkers Prev 7:689-696, 1998.

White JE, Velentgas P, Mandelson MT, Lehman CD, Elmore JG, Porter PL, Yasui Y, Taplin SH. Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. J Natl Cancer Inst 90(12):906-10, 1998.

Porter PL, Malone KE, Heagerty P, Gatti LA, Alexander GM, Firpo E J, Daling JR, Roberts JM. Expression of Cell Cycle Regulators p27kip1 and Cyclin E, Alone and in Combination, Correlate With Survival in Young Breast Cancer Patients. Nat Med 3(2):222-225, 1997.

Thomas DB, Dao Li Gao, Self SG, Allison C, Yun Tao, Mahloch J, Ray R, Qin Qin, Presley R, Porter PL. A randomized trial of breast self-examination in Shanghai: Methodology and preliminary results. J Natl Cancer Inst 89: 355-365, 1997.

Fero ML, Rivkin M, Tasch M, Porter PL, Carow CE, Firpo E, Tsai L-H, Broudy V, Permutter RM, Kaushansky K, Roberts JM. A syndrome of multi-organ hyperplasia with features of gigantism, tumorigenesis and female sterility in p27Kip1-deficient mice. Cell 85: 733-744, 1996.

Glogovac J, Porter PL, Banker D, Rabinovitch P. Cytokeratin labeling of breast cancer cells extracted from paraffin embedded tissue for bivariate flow cytometric analysis. Cytometry 24:260-267, 1996.

Iruela-Arispe ML, Porter PL, Sage EH, Bornstein P. Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium. J Clin Invest 97(2):403-12, 1996.

Porter PL, Sage EH, Lane TF, Funk SE, Gown AM. Distribution of SPARC in human normal and neoplastic tissue. J Histochem Cytochem 43(8):791-800, 1995.

Coltrera M.D, Wang J, Porter PL, Gown AM. Expression PDGF-B and the PDGF receptor beta subunit in human breast tissue and breast carcinoma. Cancer Res 55:2703-2708, 1995.

Porter PL, Gown AM, Kramp SG, Coltrera MD. Widespread p53 overexpression in human malignant tumors; an immunohistochemical study in fixed, embedded tissue. Am J Pathol 140:145-153, 1992.

Porter PL, Garcia R, Moe R, Corwin DJ, Gown AM. C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia. Cancer 68(2):331-334, 1991.
Moe RE, Moe KS, Porter PL, Gown AM, Ellis G, Tapper D. Expression of Her-2/neu oncogene protein product and epidermal growth factor receptor in surgical specimens of human breast cancers. Am Journal Surg 161:580-583, 1991.

Porter PL, Bigler SA, McNutt M, Gown AM. The immunophenotype of hemangiopericytomas and glomus tumors, with special reference to muscle protein expression: an immunohistochemical study and review of the literature. Mod Pathol 4(1):46-52, 1991.